Table 3. Demographic distribution of the patients with disease recurrence.
| TACE+sorafenib (N=127) | TACE only (N=127) | p-value | |
|---|---|---|---|
| Age (y) | 1 | ||
| <50 | 69 (54.3%) | 69 (54.3%) | |
| ≥50 | 58 (45.7%) | 58 (45.7%) | |
| Gender | 1 | ||
| Male | 116 (91.3%) | 116 (91.3%) | |
| Female | 11 (8.7%) | 11 (8.7%) | |
| AFP (μg/L) | <0.001 | ||
| <400 | 69 (54.3%) | 98 (77.2%) | |
| ≥400 | 58 (45.7%) | 29 (22.8%) | |
| Tumor size (cm) | 1 | ||
| <5 | 99 (78%) | 99 (78%) | |
| ≥5 | 28 (22%) | 28 (22%) | |
| Tumor number | 1 | ||
| Single | 54 (42.5%) | 54 (42.5%) | |
| Multiple | 73 (57.5%) | 73 (57.5%) | |
| Ascites | 8 (6.3%) | 2 (1.6%) | 0.053 |
| Hepatic Cirrhosis | 72 (56.7%) | 57 (45.2%) | 0.068 |
| PVTT | 30 (23.6%) | 4 (3.1%) | <0.001 |
| Extrahepatic metastasis | 23 (18.1%) | 15 (11.8%) | 0.159 |
| Child-Pugh | 0.058 | ||
| A | 110 (86.6%) | 119 (93.7%) | |
| B | 17 (13.4%) | 8 (6.3%) | |
| ECOG status | 0.065 | ||
| 0/1 | 115 (90.6%) | 105 (82.7%) | |
| 2 | 12 (9.4%) | 22 (17.3%) |
TACE, transarterial chemoembolization; AFP, α-fetoprotein; PVTT, portal vein tumor thrombus; ECOG, Eastern Cooperative Oncology Group